theranostics

News

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.

Oncology

Why is pharma going gaga for radiopharmaceuticals?

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.

Oncology

Are radiopharmaceuticals the next breakthrough in oncology?

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.

Partner Content

DH16HT The Cancer Imaging Centre at The University of Manchester Wolfson Molecular Imaging Centre.

Partner Content

Medicines Discovery Catapult relaunches Wolfson Radiochemist...

MDC relaunches Wolfson Radiochemistry facility

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Why is pharma going gaga for radiopharmaceuticals?

Are radiopharmaceuticals the next breakthrough in oncology?

Medicines Discovery Catapult relaunches Wolfson Radiochemist...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

theranostics

Editor's Picks